Immune response to the two doses of mRNA vaccine: A cross-sectional study from a single center located in Wasit province, Iraq

The pandemic controlling COVID-19 can cause the deaths of more than 4 million worldwide. Recently production effective vaccine genetically modified is suitable solution for managing acute respiratory syndrome, SARS-CoV-2 was a talented emergency use license by FDA company Pfizer-BioNTech (BNT162b2) mRNA CRP and D dimer important blood markers diagnosis severity this disease. specific antibody IgG measurement titer after (14-20). After intake first dose VIDAS® (BioMérieux, Marcy-L'Etoile, France), all volunteers have done screening examination rapid test detection not exposure to previous infection, who had negative IgG, second vaccine, using ELFA technique. D-dimer were used monitor assess any side effects (side on lung inflammatory clotting system), measured 48h taking in both doses. Ninety-four included study (54 female 40 male) divided into two age groups. All subjects (10 20) days following booster dose. results shown non-significant difference between males females. mean value against CoV antigen 2nd immunization significantly higher corresponding 1st There correlation ages immunized with receiving vaccine. increased vaccination while C-reactive protein decreased. Pfizer gives an excellent active immune response produce dose, recorded effect activity markers. Keywords: COVID-19; response; vaccine; protein, D-dimer, anti-SARS-CoV-2 IgG.